Supply of Covaxin to Centre at Rs 150 per dose not sustainable in long run: Bharat Biotech
Vaccine manufacturer Bharat Biotech has said the rate at which it was supplying its Covid-19 vaccine to the government was “not sustainable in the long run” and a differential price in the private markets was justified to “offset parts of the costs”. In a detailed statement over the pricing…